Cheryl Jones

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

Manish R. Patel, R. Advani, A. Hagenbeek, 2015, The Lancet. Oncology.

A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors.

M. Belvin, G. Shapiro, P. LoRusso, 2012 .

An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies.

E. Holmgren, Cheryl Jones, 2007, Contemporary clinical trials.

Abstract LB-89: Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study in patients with advanced solid tumors

M. Belvin, G. Shapiro, P. LoRusso, 2011 .

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

R. Advani, A. Hagenbeek, G. Salles, 2014 .

Exposure-Response Analysis to Assist Selection of Dose and Treatment Duration for Polatuzumab Vedotin As a Single Agent or in Combination with Rituximab for the Treatment of B-Cell Lymphoma

L. Gibiansky, S. Girish, D. Lu, 2015 .

Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors

B. Sikic, P. LoRusso, W. Ma, 2011 .